The Retatrutide Dose Ladder From 2 to 12mg

*This article is community-sourced educational material, not medical advice. Retatrutide is an investigational research peptide with an unfinished phase 3 program, and the sections below describe what the clinical trials did and what users report. Research use only.*

The dose ladder attached to retatrutide reads like a prescription because it appears in trial registries and gets quoted on forum threads, but it is really a measuring instrument with five fixed steps and four-week landings between them. Jastreboff’s phase 2 trial and the phase 3 program that followed built it to answer two questions, how much drug a person can absorb comfortably and how much weight each dose level moves. The steps are 2, 4, 6, 9, and 12mg, one rung per month, and most of the debate in the retatrutide subreddit is about where on this ladder a person belongs.

I · The trial protocol that built the ladder

The schedule now circulating as the retatrutide dose ladder comes from the phase 3 protocols that Eli Lilly filed with the trial registries, and the same sequence shows up across the community’s protocol threads as the canonical path, repeated in seven separate comments by the sub’s most prolific dosing writer. ² His phrasing is exact because he reads the schedule straight off the trial documents: “2 -> 4 -> 6 -> 9 -> 12.” [anecdotal] ² The starting point is likewise trial language: “The starting dose in the phase 3 clinical trials is 2mg.” [anecdotal] ⁵ Each rung was tested in a controlled setting, so the ladder functions as the boundary of what the evidence supports, and the community’s rule for staying inside that boundary is blunt: “I wouldn’t go above the max tested dose.” [anecdotal] ⁵

The four-week interval between steps is the trial’s titration cadence, which means the ladder is also a clock, since each rung is held for a month before the next one is considered. The commenter who runs the most detailed protocol threads in the corpus treats that cadence as the outer speed limit for the whole process: “I wouldn’t increase my dose faster than they did in the clinical trials.” [anecdotal] ⁵ He also treats it as a floor for patience, because the drug needs the month to show what it can do at the new level.

II · The phase 2 arms behind the schedule

Jastreboff’s phase 2 trial, published in the New England Journal of Medicine in 2023, tested seven arms: placebo, a flat 1mg dose, a 2 to 4 escalation, a flat 4mg start, a 2 to 4 to 8 climb, a fast 4 to 8 arm, and a full 2 to 4 to 8 to 12 ladder, each step four weeks apart. ^{1 3} At 48 weeks the average weight loss ranged from 8.7% in the flat 1mg arm to 24.2% in the group that reached 12mg, the dose-response spine later arguments draw on. ¹ Two phase 2 groups began on 4mg from day one and tolerated it well enough that phase 3 chose 2mg as the starting dose, a decision the commenter reads with dry amusement: “in the phase 3 trials everybody starts at 2mg so they must have liked the numbers there a little better.” [anecdotal] ⁵

“One of the strongest results was the treatment group that started at 4mg, went up to 8mg after four weeks, and stayed there for the rest of the trial. 44 weeks later and that group was still steadily losing weight.”

r/retatrutide protocol commentator, Community corpus, 2025

The fast escalation arm undercuts the folk wisdom that slow starts are the only safe ones, since the group that began at 4mg and stepped to 8mg after four weeks kept losing weight steadily for 44 weeks. ⁴ The same commenter pushes further: “As far as I can tell the only thing that really seems to matter for total weight loss is that you get to the max dose (or a dose sufficient to reach your goal). The timing doesn’t really seem that important.” [anecdotal] ⁴ The fixed 4mg start also posted below the escalated arms, part of why phase 3 walked the starting dose back to 2mg.

The phase 2 architecture shows tolerability shaped the ladder as much as efficacy.

III · Why the phase 3 ladder skips 8mg

The 8mg step disappeared from the schedule when the retatrutide program moved to phase 3, and the community commenter states the change flatly: “They ditched 8 entirely.” [anecdotal] ² The phase 3 protocol the sub quotes replaces the even 2 to 4 to 8 to 12 climb of phase 2 with an uneven ladder that adds 6mg and jumps from 9 to 12. ² The likely reason sits in the phase 2 numbers: the group capped at 8mg averaged 21.7% weight loss at 48 weeks, while the group that climbed to 12mg averaged 24.2%, about 11.5% more, a gap the community reads as the strongest argument that the drug does its best work at the top of the tested range. ⁵ The same commenter warns against treating 8mg as a stopping point for people who still have weight to move: “Stopping at 8mg is a mistake if you’re not getting the desired effect yet.” [anecdotal]

The newer trials consolidate the ladder into a single shape: Triumph-5, Triumph-6, and Triumph-7 run one 2 to 12mg arm with no intermediate branches, which the community reads as the sponsor voting for the full climb, and the phase 3 extension moved each remaining participant, including those who started on placebo, to 12mg. ¹⁰ The message is consistent: the ladder exists to get people to 12mg, and the intermediate rungs are acclimatization steps. One community quip sums up the ceiling question with a medical analogy: “Do you cycle your blood pressure medication?” [anecdotal] ¹⁴

The phase 3 ladder is also not a universal prescription, since the community’s own doctrine holds that a person losing steadily at 4mg has no obligation to keep climbing.

IV · The 1mg arm and the microdose debate

The most argued-about corner of the phase 2 data is the flat 1mg arm, because it produced a real average, 8.7% of body weight over 48 weeks on a single weekly milligram, and both sides of the microdose debate quote that number. ¹ The trial-following commenter cites it from the efficiency angle: “Peak bang for your buck happens at 1mg where average weight loss was 8.7%, so we get 8.7%/mg” [anecdotal] ⁵ His point is that the first milligram buys more effect per unit than any later rung, since 4mg does not produce four times the effect of 1mg and 12mg does not produce twelve times it, so the per-milligram return declines as the dose climbs. The absolute picture is the opposite, with average loss still rising to 24.2% at 12mg, which means the microdose argument and the max-dose argument are both reading the same trial and optimizing different variables, efficiency per milligram versus total effect on the scale. ¹

His verdict on the fractional-start culture is harsher than his math: “It’s like taking 1/4 of a Tylenol.” [anecdotal] ¹⁶ His warning about the subreddit’s default posture is equally direct: “This subreddit will largely insist that you need to stick to a completely ineffective microdose for four weeks.” [anecdotal] ¹⁶ The nuance that reconciles the positions is who belongs at the bottom of the ladder: for a lean person or a GLP-1 naive user, a low dose captures a meaningful share of the average effect, and the commenter says he would start such a person at 1mg “as that crowd tends to be more sensitive”, whereas for someone with a lot of weight to move, the pharma starting dose of 2mg is the floor of the conversation. [anecdotal] ⁵

The 1mg arm proves low doses are real, and the community’s working answer is a 1mg trial run for the right person while the full ladder stays in view for people with more weight to move.

V · The four-week rhythm and the buildup

The four-week interval between dose steps is the trial’s titration cadence, and it exists for a mechanical reason: retatrutide has a long half-life, so the drug builds up over several doses before serum levels settle, and week one of a new rung understates what the drug will do at week four. The commenter’s standard teaching line for the impatient new user is: “you haven’t given it a chance to build up in your system yet so the actual concentration of drug in your body is equivalent to about 2mg” [anecdotal] ⁷ His worked example gives the principle a number: a 12mg user four weeks off still carries roughly 0.85mg of the drug onboard, and a newcomer who took two 1mg doses clears to about the same level in four days. ⁷ The practical consequence is that a single weak week proves nothing, and the community’s escalation triggers mirror the cadence exactly: “If it’s been four or more weeks since your last dose increase, you’re tolerating the drug well, and you feel like the drug could be working better than it currently is: it’s a good idea to increase your dose.” [anecdotal] ⁶

The same window is also where the community pauses on purpose. The commenter who posts the ladder verbatim is the same one who points out that staying put is legitimate: “if you’re sitting there at week 4 of your current dose and thinking ‘this is working really well, I probably shouldn’t lose weight any faster’ then it makes a lot of sense to stay at that dose” [anecdotal] ⁵ The counter-rule for the stalled end: “You don’t even need to waste a month with no weight loss. If it doesn’t seem to be working as well as you’d want and you’re not having issues with side effects, go up.” [anecdotal] ⁵ The community protocol for side effects is to skip a week and let the serum level fall: “Skip a week. Let your serum levels drop to about half of where they are right now. Then come back at 1mg and go from there.” [anecdotal] ⁸ The trial investigators used the same maneuver, having participants skip a weekly dose when side effects demanded it. ⁸

The rhythm of the ladder is a feedback loop sampled monthly, with four weeks to reach steady state and four weeks to judge the effect before deciding to hold or escalate on tolerance and results rather than the calendar alone.

VI · The switcher problem at the bottom of the ladder

The most failure-prone place on the ladder is the bottom rung for people arriving from another GLP-1, and the community’s most-repeated warning covers it: “Some folks who’ve been on 15mg of tirzepatide don’t see much effect until they get up to 9mg or even 12mg” [anecdotal] ⁹ His explanation is dose equivalence, since the community’s rough scale places 2mg of retatrutide near 2.5mg of tirzepatide, so a person stepping down from 15mg amounts to dropping their prior dose to a fraction of itself, and the felt result is captured in the sub’s favorite phrase: “It’ll probably feel like you’re injecting water until you get up to 9mg or 12mg of reta.” [anecdotal] ⁹ The range where the drug registers for high-dose switchers is 6 to 12mg in the commenter’s repeated estimate, with 9mg as his middle guess for someone coming from a max tirz dose. ⁹

The protocol advice that follows is structural. The community case for switching early is that starting retatrutide first avoids the hard scenario entirely, and for high-dose switchers the expected experience is a rocky two to three month window at low doses, which is why the bridging schedules walk the tirz dose down while the reta dose climbs. ⁹ His diagnosis of the failure pattern is sharp: “I’ve seen a shocking number of people try to switch from 10+mg of tirz to 0.5mg of reta and then post about how this stupid peptide doesn’t work and they devoured a horse.” [anecdotal] ⁹

The switcher problem explains a large share of the “reta doesn’t work” complaints in the corpus, since the people posting them are often the ones who started at a fraction of their previous dose, and the community’s consistent reading is that the bottom rung is the wrong place for a high-dose switcher to judge the drug.

VII · Why 12mg became the maintenance norm

Once the weight is off, the ladder question becomes a maintenance question, and the community’s answer is unsentimental: the maintenance dose is whatever dose holds your weight where you want it. ¹² The sub’s repeated phrasing: “Your maintenance dose is a very individual thing. It’s basically just whatever dose will keep you at the weight you want to be at.” [anecdotal] ¹² For a large share of the corpus that number is 12mg, and the sub’s most detailed protocol writer states his own choice plainly: “I’ve continued at 12mg since reaching my target weight. I could probably drop the dose down but 12 is working well, I have no issues eating enough, and it’s cheap so why not?” [anecdotal] ¹¹ A second long-term user echoes it: “I’ve just been pinning 12mg once a week. It seems to work well for me so why not?” [anecdotal] ¹¹ The community’s framing of 12mg as a normal maintenance dose rests on the trial program, since the phase 3 extension moved each remaining participant, including the placebo group, to 12mg, which reads as the sponsor treating the top rung as a sustainable long-term position. ¹⁰

The tolerance question gets a clear community answer, since the phase 2 extension data showed participants plateauing a year and a half in and holding that weight for years afterward, which the commenter compresses into “tolerance isn’t an issue with GLP-1s” [anecdotal] ¹³ The corollary is that stopping the drug has a predictable cost: “Most of the folks who stop taking GLP-1s regain most of their weight in a couple years.” [anecdotal] ¹³ That is why the community frames maintenance as chronic care, with the blood pressure analogy doing the argumentative work. ¹⁴

Maintenance is individual, though, and the corpus is explicit that it can also be low, since the same commenter who runs 12mg notes that a person holding a modest loss might settle at 2mg, and the sub jokes about dialing in the exact number with a made-up goldilocks dose. ¹² [anecdotal]

The maintenance norm is a distribution rather than a rule, with most of the community settling on the upper half of the ladder and a minority holding at the bottom.

VIII · What the ladder leaves open

The ladder is not finished, and the community knows it because the trial program keeps moving. The commenter notes higher doses under study right now: “They’re testing two higher doses in a clinical trial right now. Not 100% sure but probably 20mg and 25mg.” [anecdotal] ¹⁵ Step timing is itself a variable, since Triumph-9 is testing longer step intervals against the standard four-week rhythm, which would reshape the ladder’s clock if the data favors it. ¹⁰ The phase 2 fast-escalation arm is the standing evidence that speed of titration matters less than the dose eventually reached, since that group stepped from 4 to 8mg after four weeks and kept losing weight steadily for the rest of the trial. ⁴ The open questions are honest ones: whether the 20 and 25mg doses extend the dose-response curve and whether step timing changes tolerability, with the maintenance question still open once the drug reaches pharmacy shelves.

The corpus also carries a warning about who to trust with ladder advice. The sub’s fact-check on the influencer clinician Trevor Bachmeyer found that his claims about retatrutide requiring carbohydrates rested on citations that did not exist, and the community’s rule for evaluating any dosing claim is to check the trial registries before checking a personality. ¹⁶ [anecdotal] The minimum-dose doctrine gets mocked from the other direction: “There’s a lot of overlap in the venn diagram of people who preach that you should always use the least effective dose and people who talk about reta lacking appetite suppression.” [anecdotal] ¹⁶

The article closes where the community closes, since the ladder describes the tested range while the person describes the actual dose: “The best plan is whatever actually works for you personally.” [anecdotal] The trials are still writing the manual, and for now the ladder from 2 to 12mg is the most honest map anyone has.